Genmab A (GMAB) Cash & Current Investments (2018 - 2026)

Genmab A has reported Cash & Current Investments for 7 years, with the latest figure at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 4.18% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 4.18% YoY), and the FY2025 full-year result was $1.7 billion, up 23.29% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $1.5 billion, down from $1.7 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $2.4 billion in Q4 2023, with the low at $995.0 million in Q3 2024.
• Historically, Cash & Current Investments has averaged $1.7 billion across 4 years, with a median of $1.6 billion in 2025.
• Annual changes were most pronounced in 2024 — Cash & Current Investments tumbled 42.14% — and 2025, when it soared 91.06%.
• Genmab A's Cash & Current Investments stood at $2.4 billion in 2023, then sank by 42.14% to $1.4 billion in 2024, then rose by 23.29% to $1.7 billion in 2025, then decreased by 11.31% to $1.5 billion in 2026.
• The last three Cash & Current Investments figures came in at $1.5 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.